ValuEngine upgraded shares of Sangamo BioSciences, Inc. (NASDAQ:SGMO) from a sell rating to a hold rating in a research note released on Thursday.
Other research analysts have also recently issued reports about the stock. Wedbush reiterated a neutral rating and issued a $4.00 price objective (down from $6.00) on shares of Sangamo BioSciences in a report on Tuesday, May 16th. Zacks Investment Research upgraded shares of Sangamo BioSciences from a sell rating to a hold rating in a report on Tuesday, May 16th. Cowen and Company reiterated a buy rating on shares of Sangamo BioSciences in a report on Tuesday, February 28th. Finally, Piper Jaffray Companies reiterated a neutral rating and issued a $5.00 price objective on shares of Sangamo BioSciences in a report on Tuesday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Sangamo BioSciences currently has an average rating of Hold and an average price target of $5.67.
Sangamo BioSciences (NASDAQ:SGMO) opened at 7.95 on Thursday. The firm’s market cap is $571.92 million. The company has a 50-day moving average price of $6.84 and a 200 day moving average price of $4.68. Sangamo BioSciences has a 12 month low of $2.65 and a 12 month high of $8.60.
Sangamo BioSciences (NASDAQ:SGMO) last posted its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.03. The business had revenue of $3.40 million during the quarter, compared to analysts’ expectations of $4.14 million. Sangamo BioSciences had a negative net margin of 380.44% and a negative return on equity of 50.76%. The business’s revenue was down 12.8% on a year-over-year basis. During the same period last year, the firm posted ($0.23) earnings per share. Equities research analysts anticipate that Sangamo BioSciences will post ($0.94) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Sangamo BioSciences, Inc. (SGMO) Raised to Hold at ValuEngine” was first reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2654815/sangamo-biosciences-inc-sgmo-raised-to-hold-at-valuengine.html.
Hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY boosted its stake in shares of Sangamo BioSciences by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 780 shares during the last quarter. Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Sangamo BioSciences during the first quarter worth $154,000. A.R.T. Advisors LLC acquired a new stake in shares of Sangamo BioSciences during the fourth quarter worth $161,000. Bank of America Corp DE boosted its stake in shares of Sangamo BioSciences by 49.9% in the first quarter. Bank of America Corp DE now owns 32,625 shares of the biopharmaceutical company’s stock worth $169,000 after buying an additional 10,861 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Sangamo BioSciences during the fourth quarter worth $179,000. Hedge funds and other institutional investors own 59.23% of the company’s stock.
About Sangamo BioSciences
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sangamo BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.